Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jason P. Hafler
AddedMar 31, 2024
UpdatedMay 31, 2026
Jason P. Hafler

Jason P. Hafler

Board Member, Neurovia

Crunchbase

Jason P. Hafler's Career

Neurovia
Neurovia

San Francisco, CA, US

Board Member· Board
Expansion Therapeutics
Expansion Therapeutics

Jupiter, FL, US

Board Member· Board
Abcuro
Abcuro

Newton, MA, US

Board Member· Board
Escient Pharmaceuticals
Escient Pharmaceuticals

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jason P. Hafler's Career

Neurovia
Neurovia
Public$14M752013San Francisco, CA, US
Board Member· Board

Leadership at Neurovia

Giovanni FerraraGiovanni FerraraBoard Member
Henry B. SkinnerHenry B. SkinnerBoard Member
Dan BradburyDan BradburyBoard Member

Similar to Neurovia

NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
NeuroTherapiaNeuroTherapiaOhio, IL, USTherapeuticsest. 2015NeuroTherapiaOhio, IL, US · est. 2015

NeuroTherpia, Inc.: Innovating therapies for neuroinflammatory diseases since 2015.

Series A · $11.5M4
Neurona TherapeuticsNeurona TherapeuticsSouth San Francisco, CA, USCell Therapiesest. 2008Neurona TherapeuticsSouth San Francisco, CA, US · est. 2008

Neurona Therapeutics: Leading provider of cell-based medicines for neurological disorders.

Series A · $200.3M58
Neuron23Neuron23South San Francisco, CA, USPrecision Medicinesest. 2018Neuron23South San Francisco, CA, US · est. 2018

Neuron23™ Inc.: Developing precision medicines for specific neurological and immunological diseases.

Series C · $213.5M61
Expansion Therapeutics
Expansion Therapeutics
Series A$142.2M422016Jupiter, FL, US
Board Member· Board

Leadership at Expansion Therapeutics

Laura TadvalkarLaura TadvalkarBoard Member
Kevin ForrestKevin ForrestBoard Member
Campbell MurrayCampbell MurrayBoard Member
Yujiro S. HataYujiro S. HataBoard Member
Matthew D. DisneyMatthew D. DisneyBoard Member
Scott RocklageScott RocklageBoard Member

Similar to Expansion Therapeutics

Expansion TechnologiesExpansion TechnologiesCambridge, MA, USMicroscopy Toolsest. 2015Expansion TechnologiesCambridge, MA, US · est. 2015

Expansion Technologies: Pioneering scalable nanoimaging tools for biology and medicine.

Seed · $3.5M2
858 Therapeutics858 TherapeuticsSan Diego, CA, USDrug Discoveryest. 2019858 TherapeuticsSan Diego, CA, US · est. 2019

858 Therapeutics: Innovating small molecule drugs for oncology, focusing on RNA regulation and immune response.

Series A · $80.1M27
Orbital TherapeuticsOrbital TherapeuticsCambridge, MA, USMedicines, RNA Therapiesest. 2022Orbital TherapeuticsCambridge, MA, US · est. 2022

Orbital Therapeutics: Advancing global health with innovative RNA-based medicines.

Series A · $270M33
Arrakis TherapeuticsArrakis TherapeuticsWaltham, MA, USMedicines, Therapeuticsest. 2015Arrakis TherapeuticsWaltham, MA, US · est. 2015

Waltham-based biotech firm specializing in innovative solutions for global health challenges.

Series B · $113M121
Abcuro
Abcuro
Series B$214.8M332015Newton, MA, US
Board Member· Board

Leadership at Abcuro

Alex MartinAlex MartinCEO
Darlene Deptula-HicksDarlene Deptula-HicksBoard Member
Iyona RajkomarIyona RajkomarBoard Member
Stefano GullàStefano GullàFounder
Xu YajunXu YajunBoard Member
Escient Pharmaceuticals
Escient Pharmaceuticals
Public$237.5M562018San Diego, CA, US
Board Member· Board

Leadership at Escient Pharmaceuticals

Peter HirthPeter HirthBoard Member
Joshua GrassJoshua GrassBoard Member
Kathleen Sereda GlaubKathleen Sereda GlaubBoard Member
Alain BaronAlain BaronCo-Founder
Marcus BoehmMarcus BoehmCo-Founder
Kevin RaidyKevin RaidyBoard Member

Similar to Escient Pharmaceuticals

PleoPharmaPleoPharmaPhoenixville, PA, USPharmaceuticalsest. 2020PleoPharmaPhoenixville, PA, US · est. 2020

PleoPharma: A high-ethics pharmaceutical firm dedicated to addressing significant medical needs.

Series A · $11.1M30
Inception SciencesInception SciencesSan Diego, CA, USPharmaceuticalsest. 2011Inception SciencesSan Diego, CA, US · est. 2011

Inception Sciences: Developing and marketing high-value pharmaceutical therapies for chronic diseases in the US.

Series A · $20M30

Jason P. Hafler's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Jason P. Hafler

Scott JonesScott JonesFounder · PowerfileSteve HarrickSteve HarrickBoard Member · ProductivRobert GhenchevRobert GhenchevBoard Member · Mission BioAndy WeissmanAndy WeissmanBoard Member · SpliceRobert HoweRobert HoweBoard Member · LogicSource